You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博安生物-B(06955.HK):地舒單抗注射液上市申請獲藥監局藥品審評中心受理
阿思達克 03-21 12:05
博安生物-B(06955.HK)公布,集團研發的地舒單抗注射液(BA1102)的上市申請已獲中國國家藥品監督管理局藥品審評中心受理。 BA1102是安加維(英文商品名:XGEVA)的生物類似藥。其通過與RANKL結合,抑制OPG/RANKL/RANK信號傳導通路的激活,從而達到抑制腫瘤生長和減少骨破壞的目的,用於實體腫瘤骨轉移患者或多發性骨髓瘤患者的治療,以延遲或降低骨相關事件的發生風險,以及用於治療不可手術切除或者手術切除可能導致嚴重功能障礙的骨巨細胞瘤,包括成人和骨胳發育成熟的青少年患者。 公司相信,在龐大的患者需求以及良好的臨床價值等多種因素的共同推動下,BA1102在全球範圍內將具有廣闊的市場前景。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account